Test P + Winstrol Cutting (10 weeks)

25 mg labeled testosterone propionate in 1 mL sesame oil with 20%benzylbenzoate. IM. Three men with hypogonadotropic hypogonadism, 33–53 years.

testosterone: estimated dose contribution in plasma (ng/dL).

Tmax reported; half-life inferred and rounded from the 48–72 h decline in Fig 1 (~10 to~4.5 ng/mL), about 21 h. Use 24 h as an explicit approximate shape assumption.

Calibration dose

25 mg

Reported calibration peak

1640 ng/dL

Peak timing used

12 hours

Terminal half-life used

24 hours

Reconstructed absorption rate

0.1825207 /hour

• No extra F or ester fraction; dose and observed endpoint already define the scale.
• Nominal testosterone propionate ester mass, isotope-labeled study product
• Dose scaling and repeated-dose superposition use fixed parameters; the example dose does not calibrate the curve.
• Only 3 hypogonadotropic men aged 33–53; sesame oil with 20%benzylbenzoate, not every marketed preparation.
• 24 h terminal shape is a rounded inference from late Fig 1 decline, not a paper-reported half-life. The curve cannot reproduce the plateau and all sampled points exactly.
• AUC 990±325 ng*h/mL is reported without explicit integration limit; do not fit it as AUC-infinity without additional verification.
• Tracer-to-unlabeled product and linear dose scaling are extrapolations; avoid molar conversion using ester molecular weight.
• The 24 h slower half-life is a rounded inference from the study graph, not a reported fitted parameter. The source plateau is not reproduced.
• Reconstructed AUC to infinity is about 803 ng·h/mL versus reported 990 ng·h/mL with an unspecified integration window; this does not establish profile or AUC agreement.

• Fujioka 1989 endogenous/exogenous testosterone after labeled propionate

  25 mg labeled ester IM gave labeled testosterone Cmax 16.4 ng/mL at 12 h, separate from endogenous testosterone.

• Fujioka 1986 propionate in normal men

  Isotope-specific administered testosterone and endogenous testosterone are distinct analytes; 25 mg IM dose.

Estimate testosterone-propionate-source-estimate-2026-10 · version 1

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.

Timing half-life used

9 hours

Absorption half-life assumed

2.25 hours

Reference amount for the relative scale

1 mg

• Absorption half-life is assumed to be one quarter of the slower timescale (2.25 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• 9 h is an explicit assumed human timing, not a verified measured parameter here.
• F=1 is unsupported; no unit/reference-dose endpoint established.

• Haffner 1983 stanozolol/lipoprotein metabolism

  6 mg/day human study of HDL/LDL, not stanozolol plasma Cmax.

• 2016 stanozolol metabolite characterization

  Post-oral human urine, not a blood-concentration study.

winstrol-oral-relative-timing-2026-10 · version 1